 Both sorafenib and regorafenib target BRAF wild-type and BRAF V600E mutant but the inhibition of p38 MAP kinase is a peculiar characteristic of regorafenib. A Phase I study of regorafenib as a single agent in patients with heavily pretreated CRC showed promising clinical activity with a disease control rate PR SD of 59 in evaluable patients. In the Phase III trial CORRECT, which was a randomized double-blind, placebo-controlled study comparing either regorafenib plus best supportive care BSC or placebo plus BSC, it was shown that regorafenib significantly increased overall survival OS, progression-free survival PFS and disease control rate DCR, independently of KRAS status. A major interest, given the data presented in the CORRECT trial, is to determine predictive biomarkers to indicate patients likely to benefit, or to be resistant to this anti-angiogenic compound. 